Organogenesis Holdings Q3 2026 earnings
Revenue increased sequentially but remains down sharply YoY; adjusted loss widened despite expense cuts.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $45.5M | -70% | +6.4% | Ex. 99.1, Financial Results Summary |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Advanced Wound Care | $38.2M | -73% | 84% | Revenue decline of $103.3M |
| Surgical & Sports Medicine | $7.3M | -19% | 16% | Revenue decline of $1.7M |
Margins and costs
- Gross margin 52% (prior 76%, change -24 pp)
- Operating expenses $74.9M (-42% YoY)
- One-offs in the quarter Restructuring charge $0.5M; Fair value adjustment to assets held for sale $0.9M
- Effective tax rate 0% (prior-year 2%, year-to-date 20%)
- Non-GAAP bridge Adds back stock-based compensation, inventory write-downs, restructuring, fair value adjustment, and R&D program termination costs.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash, cash equivalents and restricted cash | $26.9M | $46.8M | $94.3M | -$19.9M |
| Weighted-average common shares outstanding | 128.99M | 128.67M | 126.85M | +0.32M |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Total net revenue | $179.4M - $200.0M | $179.0M - $215.0M | Lowered midpoint by $5.3M |
What drove it
- Revenue story Revenue increased sequentially (+$2.7M) driven by Advanced Wound Care (+$2.1M) and Surgical & Sports Medicine (+$0.6M), but remains down 70% YoY.
- EPS story Net loss widened due to a $51.2M increase in loss, driven by lower revenue and higher operating expenses.
- One-off check Restructuring charge $0.5M; Fair value adjustment to assets held for sale $0.9M
The good
- Revenue increased sequentially
- Operating expenses decreased 42% YoY
The bad
- Revenue down 70% YoY
- Adjusted loss widened YoY
- Cash balance down $19.9M QoQ
The ugly
- none
Open questions
- What specific factors drove the sequential revenue increase?
- How will the company sustain operations with $26.9M in cash?
Full release
Organogenesis Holdings (ORGO) earnings release, November 5, 2026
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
CANTON, Mass.,
(November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Results Summary:
• Net revenue of $45.5 million for the third quarter of 2026, a decrease of $105.0 million compared to net revenue of $150.5 million for the third quarter of 2025. Net revenue for the third quarter of 2026 consists of: o
Net revenue from Advanced Wound Care products of $38.2 million, a decrease of 73% from the third quarter of 2025. o
Net revenue from Surgical & Sports Medicine products of $7.3 million, a decrease of 19% from the third quarter of 2025.
• Net loss of $29.6 million for the third quarter of 2026, compared to net income of $21.6 million for the third quarter of 2025, an increase in net loss of $51.2 million.
• Adjusted net loss of $29.3 million for the third quarter of 2026, compared to adjusted net income of $23.2 million for the third quarter of 2025, an increase in adjusted net loss of $52.5 million.
• Adjusted EBITDA loss of $22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of $30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of $52.5 million.
“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”
Third Quarter 2026 Financial Results:
Net product revenue for the third quarter of 2026 was $45.5 million, compared to $150.5 million for the third quarter of 2025, a decrease of $105.0 million, or 70%. The decrease in net product revenue was driven by a decrease of $103.3 million, or 73%, in net product revenue for Advanced Wound Care products.
Gross profit for the third quarter of 2026 was $23.6 million, or 52% of net product revenue, compared to $114.2 million, or 76% of net product revenue for the third quarter of 2025, a decrease of $90.7 million, or 79%.
Operating expenses for the third quarter of 2026 were $74.9 million compared to $130.1 million for the third quarter of 2025, a decrease of $55.2 million, or 42%. Cost of goods sold was $21.9 million for the third quarter of 2026, compared to $36.3 million for the third quarter of 2025, a decrease of $14.4 million, or 40%.
Selling, general and administrative expenses were $45.1 million for the third quarter of 2026, compared to $79.7 million for the third quarter of 2025, a decrease of $34.7 million, or 43%. R&D expense was $8.0 million for the third quarter of 2026, compared to $13.2 million for the third quarter of 2025, a decrease of $5.3 million, or 40%.
Operating loss for the third quarter of 2026 was $29.5 million, compared to an operating income of $20.7 million for the third quarter of 2025, an increase in operating loss of $50.2 million.
Total other expense, net, for the third quarter of 2026 was $0.1 million, compared to total other income, net, of $0.4 million for the third quarter of 2025, a decrease of $0.6 million.
Net loss for the third quarter of 2026 was $29.6 million, or $(0.25) per share, compared to net income of $21.6 million, or $0.11 per share, for the third quarter of 2025, an increase in net loss of $51.2 million, or $(0.36) per share.
Adjusted net loss was $29.3 million for the third quarter of 2026, compared to adjusted net income of $23.2 million for the third quarter of 2025, an increase in adjusted net loss of $52.5 million.
Adjusted EBITDA loss was $22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of $30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of $52.5 million.
Non-GAAP operating loss was $29.1 million for the third quarter of 2026, compared to non-GAAP operating income of $23.0 million for the third quarter of 2025, an increase in non-GAAP operating loss of $52.1 million.
Nine Months Ended September 30, 2026 Financial Results:
Net product revenue for the nine months ended September 30, 2026 was $124.5 million, compared to $338.0 million for the nine months ended September 30, 2025, a decrease of $213.4 million, or 63%. The decrease in net product revenue was driven by a decrease of $210.3 million, or 67%, in net product revenue for Advanced Wound Care products.
Gross profit for the nine months ended September 30, 2026 was $53.2 million, or 43% of net product revenue, compared to $250.4 million, or 74% of net product revenue for the nine months ended September 30, 2025, a decrease of $197.2 million, or 79%.
Operating expenses for the nine months ended September 30, 2026 were $275.8 million compared to $357.2 million for the nine months ended September 30, 2025, a decrease of $81.3 million, or 23%. Cost of goods sold was $71.3 million for the nine months ended September 30, 2026, compared to $87.6 million for the nine months ended September 30, 2025, a decrease of $16.3 million, or 19%.... (truncated)ion, or 27%. R&D expense was $41.4 million for the nine months ended September 30, 2026, compared to $34.3 million for the nine months ended September 30, 2025, an increase of $7.2 million, or 21%.
Operating loss for the nine months ended September 30, 2026 was $149.4 million, compared to an operating loss of $18.6 million for the nine months ended September 30, 2025, an increase in operating loss of $130.8 million.
Total other income, net, for the nine months ended September 30, 2026 was $0.4 million, compared to $2.1 million for the nine months ended September 30, 2025, a decrease of $1.7 million.
Net loss for the nine months ended September 30, 2026 was $179.1 million, or $(1.47) per share, compared to net loss of $6.7 million, or $(0.12) per share, for the nine months ended September 30, 2025, an increase in net loss of $172.4 million, or $(1.35) per share.
Adjusted net loss was $162.1 million for the nine months ended September 30, 2026, compared to adjusted net income of $2.3 million for the nine months ended September 30, 2025, an increase in adjusted net loss of $164.4 million.
Adjusted EBITDA loss was $104.9 million for the nine months ended September 30, 2026, compared to Adjusted EBITDA income of $14.0 million for the nine months ended September 30, 2025, an increase in Adjusted EBITDA loss of $118.9 million.
Non-GAAP operating loss was $126.1 million for the nine months ended September 30, 2026, compared to non-GAAP operating loss of $6.3 million for the nine months ended September 30, 2025, an increase in non-GAAP operating loss of $119.8 million.
As of September 30, 2026, the Company had $26.9 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2025.
Fiscal Year 2026 Outlook:
For the year ending December 31, 2026, the Company now expects:
• Total net revenue between $179.4 million and $200.0 million, representing a decline in the range of 65% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025. o
Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the fourth quarter, however, at a more measured rate versus what our prior guidance assumed, resulting in a second half revenue decline in the range of approximately 68% to 74% year over year, and compared to our prior guidance range which assumed a decline in the range of 64% to 74% year-over-year.
Third Quarter Earnings Conference Call:
Management will host a conference call at 5:00 p.m. Eastern Time on November 5th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
ORGANOGENESIS HOLDINGS INC.
UNAUDITED CONDENSED CONSOLIDATED BA
LANCE SHEETS
(amounts in thousands, except share and per share data)
Financial statements
Income Statement
Three Months Ended September 30, — (amounts in thousands, except share and per share data)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Revenue: | ||||
| Net product revenue | 45,457 | 150,487 | 124,512 | 337,959 |
| Grant income | 377 | 1,928 | 603 | |
| Total revenue | 45,457 | 150,864 | 126,440 | 338,562 |
| Operating expenses: | ||||
| Cost of goods sold | 21,898 | 36,251 | 71,343 | 87,604 |
| Selling, general and administrative | 45,087 | 79,743 | 164,238 | 226,062 |
| Research and development | 7,961 | 13,221 | 41,419 | 34,256 |
| Fair value adjustment to assets held for sale | 922 | -1,188 | 9,235 | |
| Total operating expenses | 74,946 | 130,137 | 275,812 | 357,157 |
| Income (loss) from operations | -29,489 | 20,727 | -149,372 | -18,595 |
| Other income (expense), net: | ||||
| Interest income (expense), net | -61 | 415 | 457 | 2,045 |
| Other income (expense), net | -71 | 18 | -59 | 93 |
| Total other income (expense), net | -132 | 433 | 398 | 2,138 |
| Net income (loss) before income taxes | -29,621 | 21,160 | -148,974 | -16,457 |
| Income tax benefit (expense) | -8 | 407 | -30,078 | 9,789 |
| Net income (loss) and comprehensive income (loss) | -29,629 | 21,567 | -179,052 | -6,668 |
| Accretion of redeemable convertible preferred stock to redemption value | -181 | -140 | -510 | -390 |
| Cumulative dividend on redeemable convertible preferred stock | -2,959 | -2,734 | -8,705 | -8,042 |
| Undistributed earnings allocated to participating redeemable convertible preferred stock | -4,168 | |||
| Net income (loss) attributable to common stockholders | -32,769 | 14,525 | -188,267 | -15,100 |
| Net income (loss) per share: | ||||
| Basic | -0.25 | 0.11 | -1.47 | -0.12 |
| Diluted | -0.25 | 0.11 | -1.47 | -0.12 |
| Weighted-average common shares outstanding: | ||||
| Basic | 128,990,436 | 126,881,709 | 128,489,389 | 126,679,109 |
| Diluted | 128,990,436 | 130,848,995 | 128,489,389 | 126,679,109 |
Income Statement
Three Months Ended September 30, — The following table presents a reconciliation of GAAP income (loss) from operations to non-GAAP operating income (loss), for the periods presented: (in thousands)
| Three Months Ended September 30, – 2026 – (Unaudited, in thousands) | Three Months Ended September 30, – 2025 – (Unaudited, in thousands) | Nine Months Ended September 30, – 2026 – (Unaudited, in thousands) | Nine Months Ended September 30, – 2025 – (Unaudited, in thousands) | |
|---|---|---|---|---|
| Income (loss) from operations | -29,489 | 20,727 | -149,372 | -18,595 |
| Amortization of intangible assets (1) | 433 | 842 | 6,574 | 2,525 |
| Inventory write-downs (2) | 3,327 | |||
| Restructuring charge (3) | 516 | 8,957 | 516 | |
| Fair value adjustment to assets held for sale (4) | 922 | -1,188 | 9,235 | |
| R&D program termination costs (5) | 5,588 | |||
| Non-GAAP operating income (loss) | -29,056 | 23,007 | -126,114 | -6,319 |
Balance Sheet
September 30, — (amounts in thousands, except share and per share data)
| September 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 21,326 | 93,679 |
| Restricted cash | 163 | 652 |
| Accounts receivable, net | 92,687 | 217,451 |
| Inventories, net | 26,683 | 29,627 |
| Asset held for sale | 2,425 | |
| Prepaid expenses and other current assets | 17,268 | 18,354 |
| Total current assets | 158,127 | 362,188 |
| Property and equipment, net | 98,600 | 103,711 |
| Intangible assets, net | 2,571 | 9,145 |
| Goodwill | 28,772 | 28,772 |
| Operating lease right-of-use assets, net | 47,808 | 55,749 |
| Deferred tax asset, net | 29,962 | |
| Other assets | 33,027 | 9,203 |
| Total assets | 368,905 | 598,730 |
| Current liabilities: | ||
| Current portion of finance lease obligations | 897 | 9,435 |
| Current portion of operating lease obligations - related party | 4,846 | 4,258 |
| Current portion of operating lease obligations | 3,569 | 4,949 |
| Accounts payable | 22,478 | 31,949 |
| Accrued expenses and other current liabilities | 15,859 | 49,533 |
| Total current liabilities | 47,649 | 100,124 |
| Finance lease obligations, net of current portion | 10,372 | 12,788 |
| Operating lease obligations, net of current portion - related party | 24,472 | 28,237 |
| Operating lease obligations, net of current portion | 20,360 | 22,470 |
| Other liabilities | 3,311 | 1,193 |
| Total liabilities | 106,164 | 164,812 |
| Commitments and contingencies (Note 15) | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; 130,000 shares authorized, issued and outstanding; liquidation preference of $150,922 and $142,217 at September 30, 2026 and December 31, 2025, respectively. | 143,004 | 133,789 |
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 400,000,000 shares authorized; 130,522,276 and 127,680,424 shares issued; 129,793,728 and 126,951,876 shares outstanding at September 30, 2026 and December 31, 2025, respectively. | 13 | 13 |
| Additional paid-in capital | 302,164 | 303,194 |
| Accumulated deficit | -182,440 | -3,078 |
| Total stockholders’ equity | 119,737 | 300,129 |
Cash Flow
Nine Months Ended September 30, — (amounts in thousands, except share and per share data)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | -179,052 | -6,668 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 11,769 | 11,207 |
| Amortization of intangible assets | 6,574 | 2,525 |
| Reduction in the carrying value of right-of-use assets | 7,071 | 6,193 |
| Non-cash interest expense | 211 | 208 |
| Deferred tax expense (benefit) | 29,962 | -6,129 |
| Provision recorded for credit losses | 1,161 | 5,403 |
| Loss on disposal of property and equipment | 723 | 73 |
| Adjustment for excess and obsolete inventories | 12,639 | 7,963 |
| Stock-based compensation | 9,494 | 8,974 |
| Fair value adjustment to assets held for sale | -1,188 | 9,235 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 123,603 | -64,325 |
| Inventories | -14,746 | -14,954 |
| Prepaid expenses and other current assets and other assets | 6,924 | -3,298 |
| Operating leases | -5,798 | -6,302 |
| Accounts payable | -6,922 | 643 |
| Accrued expenses and other current liabilities | -31,731 | -1,943 |
| Other liabilities | 186 | 1,466 |
| Net cash used in operating activities | -29,120 | -49,729 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | -5,712 | -9,499 |
| Sale of asset held for sale | 3,612 | |
| Net cash used in investing activities | -2,100 | -9,499 |
| Cash flows from financing activities: | ||
| Payments of withholding taxes in connection with RSUs vesting | -3,050 | -1,798 |
| Proceeds from the exercise of stock options | 155 | |
| Principal repayments of finance lease obligations | -10,598 | -869 |
| Issuance of common stock in connection with the ATM facility, net of offering costs | 1,432 | |
| Construction of landlord assets, net of tenant allowance | -23,958 | -10,039 |
| Net cash used in financing activities | -36,174 | -12,551 |
| Change in cash, cash equivalents and restricted cash | -67,394 | -71,779 |
| Cash, cash equivalents, and restricted cash, beginning of period | 94,331 | 136,151 |
| Cash, cash equivalents, and restricted cash, end of period | 26,937 | 64,372 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $— | 4,086 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | 9,215 | 8,432 |
| Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | -236 | -2,029 |
| Right-of-use assets obtained through finance lease obligations | -357 | 2,282 |
| Right-of-use assets obtained through operating lease obligations | $— | 2,388 |
| Deemed dividend for anti-dilution adjustment to convertible preferred stock | 310 | $— |
| Landlord asset additions included in accounts payable and accrued expenses and other current liabilities, net of tenant allowances | 2,909 | 1,925 |